Anti-androgen hormonal therapy for cancer and other diseases
The development of targeted therapies has been a consistent goal for hormone-related diseases treatment. The concept of hormonal therapy in prostate cancer (PCa) treatment was born in the 1940s, when it was proven that patients benefited from castration and estrogen injection what finally resulted in therapy with GnRH agonists.

Androgens play an important role in different disorders, therefore, androgen receptor signalling is a crucial factor in pathological conditions. The androgen receptor is a transcription factor activated by the testosterone metabolite 5α-dihydrotestosterone and regulates the expression of genes related to sexual differentiation, growth and survival of prostate cells, and to a certain extent, cancer progression.

This review discusses anti-androgen therapies in cancer and other selected diseases and provide examples where anti-androgen drugs can be used as both main and supportive treatments in the multimodal therapeutic scheme. Even in diseases with low serum levels of testosterone or DHT, anti-androgen therapy plays an important role in new treatments. Therefore, the use of anti-androgens is an appealing strategy in which to overcome resistance to primary treatment by assuring better therapy results.